Untitled

Wyss Institute Search Site

Technologies 4

NanoRx: Mechanically-Activated Drug Targeting
The Wyss team has developed a novel drug targeting nanotechnology that is activated locally by mechanical forces, either endogenous high shear stresses in blood created by vascular occlusion or mechanical energy applied locally using low-energy ultrasound radiation. Today, vascular blockage is the leading cause of death and disability in United States and Europe. Current therapies...
Microfluidic Hemostasis Monitor
The body’s ability to stop bleeding, also known as hemostasis, is critical for survival. For patients with blood clotting disorders, medical conditions requiring the use of anticoagulation or antiplatelet drugs, or who require treatment with extracorporeal devices that circulate their blood outside of the body, it is essential that care providers can rapidly monitor their...
Omniphobic material that empowers a new category of medical devices
Cerulean Scientific is using our thin layer perfluorocarbon technology to develop medical devices that resist clotting, obstruction and infection, reducing patient suffering and lowering healthcare costs for the 10% of the population treated with an implantable medical device.
Human Organs-on-Chips
Organ Chips are microfluidic devices lined with living human cells for drug development, disease modeling, and personalized medicine. Launched in 2014, Wyss startup Emulate, Inc., is leveraging the Wyss Institute’s Organ Chip technology to mimic human organs in vitro, enabling faster, better, and cheaper drug development and insights into human health.

News 19

Multimedia 7